Australia's most trusted
source of pharma news
Posted 5 November 2024 AM
Despite winning a surprisingly broad indication for Idefirix in Australia, Hansa Biopharma has hit yet another hurdle in gaining public funding for the kidney desensitisation treatment.
An application requesting funding for Idefirix under the National Health Reform Agreement was knocked back by the Medical Services Advisory Committee (MSAC) in October 2023 after being considered at the July 2023 meeting. Idefirix is intended as a desensitisation treatment of highly sensitised (HS) adult kidney transplant patients with a positive crossmatch against an available deceased or living donor who are unlikely to be transplanted under current kidney allocation systems.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.